TY - JOUR AU - Lipson, Victoria AU - Kulyk, Karyna PY - 2021/09/21 Y2 - 2024/03/29 TI - Low molecular weight gelators based on steroid derivatives and pentacyclic triterpenoids JF - Kharkiv University Bulletin. Chemical Series JA - Khark. Univ. Bull. Chem. Ser. VL - IS - 37 SE - Articles DO - 10.26565/2220-637X-2021-37-02 UR - https://periodicals.karazin.ua/chemistry/article/view/18768 SP - 19-31 AB - The article is an overview of the latest achievements in the study of low molecular weight gelling agents based on steroids - cholesterol, estradiol, dehydroepi-androsterone and pentacyclic triterpenoids - arjunolic, glycyrrhetinic acids. These compounds are used as components of smart gels and are of interest for supramolecular chemistry. A gelling agent is a substance that is able to bind various solvents at low concentrations, and the resulting gel has a solid structure which rheological properties are similar to those of solids. Non-covalent interactions: dipole-dipole, van der Waals, electrostatic, hydrogen bonds and π-stacking, are considered as the driving forces for the formation a fibrous network by low molecular weight gelator. In contrast to decades of research into the gelation of polymers, proteins and inorganic substances, low molecular weight organic gelling agents have only recently begun to be actively studied. Their chemical structure is derived from urea, amino acids, carbohydrates, cholesterol and bile acids. Unlike steroid-based gels, information on the use of pentacyclic triterpenoids for the development of low molecular weight gelling agents is extremely limited. The interest in such systems is due to the fact that, like steroids, they have a developed, rigidly organized nanosized molecular platform, making them capable of self-association in polar and nonpolar organic solvents. In addition, the presence of molecules of these compounds in several functional groups that are easily chemically modified, low toxicity and biocompatibility allows them to be considered as promising starting materials for the pharmaceutical industry, in particular for the development of mild dosage forms. ER -